

# The safest upper limit of triglycerides in the plasma

**Mehmet Rami Helvaci** (1)

**Abdulrazak Abyad** (2)

**Lesley Pocock** (3)

(1) Specialist of Internal Medicine, MD

(2) Middle-East Academy for Medicine of Aging, MD

(3) medi-WORLD International

## Corresponding author

Dr Mehmet Rami Helvaci,

07400, ALANYA,

Turkey

Phone: 00-90-506-4708759

Email: mramihelvaci@hotmail.com

Received: November 2019; Accepted: December 2019; Published: January 1, 2020.

Citation: Mehmet Rami Helvaci, Abdulrazak Abyad, Lesley Pocock. The safest upper limit of triglycerides in the plasma.

World Family Medicine. 2020; 18(1): 16-22. DOI: 10.5742MEWFM.2020.93726

## Abstract

**Background:** We tried to understand the safest upper limit of triglycerides in the plasma.

**Methods:** Patients with plasma triglycerides lower than 60 mg/dL were put into the first, lower than 100 mg/dL into the second, lower than 150 mg/dL into the third, lower than 200 mg/dL into the fourth, and 200 mg/dL or greater into the fifth groups, respectively.

**Results:** The study included 875 cases (370 males). Although the mean age increased just up to plasma triglycerides value of 200 mg/dL, male ratio and smoking increased parallel to increased plasma triglycerides values, continuously. Interestingly, the most significant increase of smoking was seen just after plasma triglycerides value of 200 mg/dL, and there was no significant effect of aging or excess weight on this step. Mean body mass index was only normal in patients with plasma triglycerides values lower than 60 mg/dL. Although fasting plasma glucose (FPG), hypertension (HT), diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), and chronic renal disease (CRD) increased parallel to the increased plasma triglycerides continuously, low density lipoproteins (LDL), white coat hypertension (WCH), and coronary heart disease (CHD) increased just up to plasma triglycerides value of 200 mg/dL.

**Conclusions:** Plasma triglycerides may behave as acute phase reactants indicating disseminated endothelial injury and atherosclerosis. FPG, LDL, WCH, HT, DM, COPD, CHD, and CRD were all deteriorated parallel to the increased male ratio, smoking, aging, excess weight, and plasma triglycerides values. Interestingly, the greatest number of deteriorations were observed just above the plasma triglycerides value of 60 mg/dL.

**Key words:** Triglycerides, male gender, smoking, excess weight, early aging, premature death

## Introduction

Chronic low-grade endothelial injury may be the most common type of vasculitis, and the leading cause of aging in human beings (1-4). Much higher blood pressure (BP) of the afferent vasculature may be the major underlying cause by inducing recurrent injuries on endothelium. Probably whole afferent vasculature including capillaries are mainly involved in the process. Thus the term of venosclerosis is not as famous as atherosclerosis in the literature. Secondary to the chronic low-grade endothelial injury, inflammation, edema, and fibrosis, vascular walls thicken, their lumens narrow, and they lose their elastic nature, all of which reduces blood supply to the end-organs, and increases systolic BP further. Some of the well-known underlying causes and indicators of the inflammatory process are physical inactivity, animal-rich diet, overweight, smoking, alcohol, hypertriglyceridemia, hyperbeta lipoproteinemia, impaired fasting glucose, impaired glucose tolerance, white coat hypertension (WCH), cancers, prolonged infections such as tuberculosis, and chronic inflammations such as rheumatologic disorders (5, 6). Some of the irreversible consequences of the chronic low-grade inflammatory process include obesity, hypertension (HT), diabetes mellitus (DM), cirrhosis, peripheral artery disease (PAD), chronic obstructive pulmonary disease (COPD), chronic renal disease (CRD), coronary heart disease (CHD), mesenteric ischemia, osteoporosis, stroke, other end-organ insufficiencies, early aging, and premature death (7-9). Although early withdrawal of the underlying factors may delay terminal consequences, after development of cirrhosis, COPD, CRD, CHD, PAD, stroke, or early aging, endothelial destruction cannot be reversed effectively due to its fibrotic nature. The triggering etiologies and terminal consequences of the chronic low-grade inflammatory process are researched under the titles of metabolic syndrome, aging syndrome, or accelerated endothelial damage syndrome in the literature, extensively (10-13). Although its normal limits could not be determined clearly yet, high plasma triglycerides values may be significant indicators of the syndrome (14). Due to the significant association between high plasma triglycerides values and CHD, Adult Treatment Panel (ATP) III adopts lower cutpoints for triglycerides abnormalities than did ATP II (15, 16). Although ATP II determined the normal upper limit of triglycerides as 200 mg/dL in 1994, World Health Organisation in 1999 (17) and ATP III in 2001 reduced the normal upper limit as 150 mg/dL (16). Although these cutpoints are usually used to define borders of the metabolic syndrome, there are suspicions about the safest upper limit of the triglycerides in the plasma. We tried to understand the safest upper limit of plasma triglycerides according to some components of the metabolic syndrome in the present study.

## Materials and Methods

The study was performed in the Internal Medicine Polyclinic of the Dumlupinar University between August 2005 and March 2007. Consecutive patients above the age of 15 years were studied. Their medical histories

were learnt, and a routine check up procedure including fasting plasma glucose (FPG), serum creatinine, liver function tests, markers of hepatitis viruses A, B, C and human immunodeficiency virus, triglycerides, low density lipoproteins (LDL), high density lipoproteins (HDL), an electrocardiogram, and an abdominal ultrasonography were performed. A Doppler echocardiogram was performed just in required cases. Current daily smokers with six pack-months and cases with a history of three pack-years were accepted as smokers. Patients with devastating illnesses including type 1 DM, malignancies, hemodialysis, ascites, hyper- or hypothyroidism, and heart failure were excluded to avoid their possible effects on weight. Additionally, anti-hyperlipidemic drugs, metformin, and/or acarbose users were excluded to avoid their possible effects on blood lipid profiles or body weight (18, 19). Body mass index (BMI) of each case was calculated by the measurements of the same physician instead of verbal expressions. Weight in kilograms is divided by height in meters squared (16). Cases with an overnight FPG level of 126 mg/dL or greater on two occasions or already using antidiabetic medications were defined as diabetics (16). An oral glucose tolerance test with 75-gram glucose was performed in cases with a FPG level between 110 and 126 mg/dL, and diagnosis of cases with a 2-hour plasma glucose level of 200 mg/dL or greater is DM (16). CRD is diagnosed with a persistently elevated serum creatinine level of 1.3 mg/dL in males and 1.2 mg/dL in females. Additionally, office blood pressure (OBP) was checked after a 5-minute rest in seated position with a mercury sphygmomanometer on three visits, and no smoking was permitted during the previous 2 hours. A 10-day twice daily measurement of blood pressure at home (HBP) was obtained in all cases after a 10 minute education session about proper BP measurement techniques (20). An additional 24 hour ambulatory blood pressure monitoring was not required due to its similar effectivity with the HBP measurements (3). Eventually, HT is defined as a mean BP of 135/85 mmHg or higher on HBP measurements, and WCH as an OBP of 140/90 mmHg or higher but a mean HBP measurement of lower than 135/85 mmHg (20). An exercise electrocardiogram was performed just in cases with an abnormal electrocardiogram and/or angina pectoris. Coronary angiography was taken just for the exercise electrocardiogram positive cases. So CHD is diagnosed either angiographically or with the Doppler echocardiographic findings as the already developed movement disorders in the cardiac walls. The spirometric pulmonary function tests were performed in required cases and the criterion for diagnosis of COPD is post-bronchodilator forced expiratory volume in one second/forced vital capacity of less than 70% (21). Eventually, patients with plasma triglycerides values of lower than 60 mg/dL were put into the first, lower than 100 mg/dL into the second, lower than 150 mg/dL into the third, lower than 200 mg/dL into the fourth, and 200 mg/dL or higher into the fifth groups, respectively. The mean age, male ratio, smoking, BMI, FPG, triglycerides, LDL, HDL, WCH, HT, DM, COPD, CHD, and CRD were detected in each group and compared in between. Mann-Whitney U test, Independent-Samples T test, and comparison of proportions were used as the methods of statistical analyses.

## Results

The study included 875 patients (505 females and 370 males), totally. The mean values of plasma triglycerides were 51.0, 78.3, 122.2, 174.1, and 325.8 mg/dL in the five groups, respectively. The mean age increased just up to the plasma triglycerides value of 200 mg/dL, and there was an increase of triglycerides about 7.8 mg/dL for each year of aging. Whereas the male ratio increased parallel to the increased plasma triglycerides values, continuously (30.9% versus 51.2%,  $p < 0.001$ ). Beside that the mean BMI values were 24.6, 27.1, 29.4, 29.9, and 30.0 kg/m<sup>2</sup> in the five groups, respectively. In other words, only the cases with the plasma triglycerides values lower than 60 mg/dL had a normal mean BMI value. Although FPG, HT, DM, COPD, and CRD increased parallel to the increased plasma triglycerides values continuously, LDL, WCH, and CHD increased just up to the plasma triglycerides value of 200 mg/dL. Interestingly, the mean HDL values were similar in all of the five groups ( $p > 0.05$  between all). Prevalence of smoking increased parallel to the increased plasma triglycerides values, continuously (16.6% versus 38.3%,  $p < 0.001$ ). Interestingly, the most significant increase of smoking was seen just after the plasma triglycerides value of 200 mg/dL, and there was no significant effect of aging or excess weight on this step. On the other hand, the greatest number of deteriorations (ten components, significantly) was observed during passage from the first into the second groups of the study cases. Whereas seven components deteriorated during passage from the second into the third groups, significantly. Although five components deteriorated during passage from the third into the fourth and from the fourth into the fifth groups, significantly, there was an additional improvement in the LDL values during the passage from the fourth into the fifth groups. Thus the number of deteriorations at this step was accepted as four (Table 1).

## Discussion

Excess weight may be the most common cause of vasculitis worldwide, and the leading cause of major health problems in this century. It leads to structural and functional abnormalities in many organ systems of the body (22). Adipose tissue produces leptin, tumor necrosis factor- $\alpha$ , plasminogen activator inhibitor-1, and adiponectin-like cytokines, all of which behave as acute phase reactants in the plasma (23). Excess weight-induced chronic low-grade vascular endothelial inflammation may play a significant role in the pathophysiology of accelerated atherosclerotic process in the whole body (1, 2). On the other hand, excess weight may cause an increased blood volume as well as an increased cardiac output thought to be the result of an increased oxygen need of the excessive fat tissue. The prolonged increase in the blood volume may lead to myocardial hypertrophy, terminating with a decreased cardiac compliance. Beside that FPG and total cholesterol values increased parallel to the increased BMI (24). Combination of these cardiovascular risk factors will eventually terminate with an increase in left ventricular

stroke work and higher risks of arrhythmias, cardiac failure, and sudden cardiac death. Similarly, the prevalence of CHD and stroke increased parallel to the increased BMI values in another study (25), and risk of death from all causes including cancers increased throughout the range of moderate to severe weight excess in all age groups (26). The relationships between excess weight, increased BP, and higher plasma triglycerides values are described in the metabolic syndrome, extensively (14), and clinical manifestations of the syndrome include obesity, hypertriglyceridemia, hyperbetalipoproteinemia, HT, insulin resistance, and proinflammatory and prothrombotic states (12). Similarly, prevalence of smoking (42.2% versus 28.4%,  $p < 0.01$ ), excess weight (83.6% versus 70.6%,  $p < 0.01$ ), DM (16.3% versus 10.3%,  $p < 0.05$ ), and HT (23.2% versus 11.2%,  $p < 0.001$ ) were all higher in the hypertriglyceridemia group in another study (27). On the other hand, the prevalence of hyperbetalipoproteinemia was similar both in the hypertriglyceridemia (200 mg/dL or greater) and control groups (18.9% versus 16.3%,  $p > 0.05$ , respectively) in the above study (27). Similarly, plasma LDL values increased just up to the plasma triglycerides value of 200 mg/dL but no more in the present study. Beside that, the mean BMI values increased just up to the plasma triglycerides value of 150 mg/dL, significantly ( $p < 0.05$  for each step). In our opinion, although excess weight does not affect each individual with the same severity, overweight, obesity, severe obesity, and morbid obesity histories of years should be added into the calendar age with various degrees during calculation of physiological age of the individuals.

Smoking and alcohol may be the second and third most common causes of vasculitis, respectively. According to our experience, both of them should be included into the major components of the metabolic syndrome since they cause chronic inflammation on the vascular endothelium, terminating with an accelerated atherosclerotic process all over the body. Smoking's destructive effects are particularly prominent in the respiratory tract and lungs, probably due to the highest concentrations of toxic substances found in the cigarette smoke. The strong and irreversible atherosclerotic effects of smoking are most clearly detected in Buerger's disease. It is an obliterative vasculitis characterized by inflammatory changes in the small and medium-sized arteries and veins, and it has never been reported in the absence of smoking in the literature. Eventually, the atherosclerotic effects terminate with early aging, end-organ insufficiencies, and premature death. According to our clinical observations, although smoking does not affect each individual with the same severity, the smoking history of pack-years should be added into the calendar age during calculation of physiological age of the patients. Probably, alcohol gives harm to vascular endothelium in similar ways with smoking but alcohol's main targets are the gastrointestinal tract and liver due to the highest concentrations of alcohol and its products there. Thus the drinking history of drink-years should also be added into the calendar age during calculation of physiological age of the patients. Due to the very low prevalence of alcoholism in Turkey (28), we did not include regular alcohol intake

Table 1: Characteristics features of the study cases according to the plasma triglycerides values

Variable	Lower than 60 mg/dL	p-value	Lower than 100 mg/dL	p-value	Lower than 150 mg/dL	p-value	Lower than 200 mg/dL	p-value	200 mg/dL or greater
Number of cases	84		207		235		148		201
<u>Age (year)</u>	<u>35.6 ± 16.4</u> (17-79)	<u>0.000</u>	<u>43.6 ± 17.5</u> (16-83)	<u>0.009</u>	<u>47.7 ± 15.3</u> (16-82)	<u>0.018</u>	<u>51.2 ± 12.6</u> (19-82)	Ns*	<u>49.8 ± 12.3</u> (19-88)
<u>Male ratio</u>	<u>30.9%</u>	<u>0.05&gt;</u>	<u>39.1%</u>	Ns	<u>40.4%</u>	Ns	<u>43.9%</u>	<u>0.05&gt;</u>	<u>51.2%</u>
<u>Smoking</u>	<u>16.6%</u>	Ns	<u>21.7%</u>	Ns	<u>26.3%</u>	Ns	<u>23.6%</u>	<u>0.001&gt;</u>	<u>38.3%</u>
<u>BMI† (kg/m²)</u>	<u>24.6 ± 5.3</u> (16.7-45.9)	<u>0.002</u>	<u>27.1 ± 5.9</u> (16.7-49.3)	<u>0.000</u>	<u>29.4 ± 6.1</u> (18.4-51.0)	Ns	<u>29.9 ± 4.8</u> (19.2-49.0)	Ns	<u>30.0 ± 5.0</u> (21.0-51.1)
<u>FPG‡ (mg/dL)</u>	<u>96.5 ± 35.3</u> (71-377)	<u>0.016</u>	<u>106.5 ± 42.7</u> (56-400)	Ns	<u>106.8 ± 35.1</u> (71-335)	<u>0.006</u>	<u>117.3 ± 47.8</u> (68-386)	Ns	<u>124.3 ± 55.3</u> (74-392)
<u>Triglycerides (mg/dL)</u>	<u>51.0 ± 7.5</u> (27-59)	<u>0.000</u>	<u>75.3 ± 10.8</u> (60-59)	<u>0.000</u>	<u>122.2 ± 14.5</u> (100-149)	<u>0.000</u>	<u>174.1 ± 14.2</u> (150-199)	<u>0.000</u>	<u>325.8 ± 160.4</u> (200-1.350)
<u>LDL§ (mg/dL)</u>	<u>98.6 ± 23.3</u> (56-161)	<u>0.000</u>	<u>114.6 ± 33.0</u> (31-269)	<u>0.000</u>	<u>131.1 ± 31.7</u> (56-228)	<u>0.033</u>	<u>137.5 ± 32.4</u> (50-237)	<u>0.020</u>	<u>129.0 ± 40.8</u> (10-239)
<u>HDL   (mg/dL)</u>	<u>44.9 ± 12.3</u> (24-77)	Ns	<u>48.8 ± 11.6</u> (33-91)	Ns	<u>46.4 ± 10.5</u> (27-80)	Ns	<u>43.7 ± 9.0</u> (22-67)	Ns	<u>43.1 ± 9.1</u> (25-70)
<u>WCH**</u>	<u>17.8%</u>	<u>0.05&gt;</u>	<u>24.1%</u>	<u>0.05&gt;</u>	<u>31.0%</u>	Ns	<u>35.1%</u>	Ns	<u>32.3%</u>
<u>HT***</u>	<u>8.3%</u>	<u>0.001&gt;</u>	<u>15.9%</u>	<u>0.05&gt;</u>	<u>21.2%</u>	Ns	<u>22.2%</u>	Ns	<u>26.3%</u>
<u>DM****</u>	<u>2.3%</u>	<u>0.001&gt;</u>	<u>11.1%</u>	Ns	<u>13.6%</u>	Ns	<u>18.2%</u>	<u>0.05&gt;</u>	<u>24.3%</u>
<u>COPD*****</u>	<u>4.7%</u>	<u>0.01&gt;</u>	<u>9.1%</u>	<u>0.01&gt;</u>	<u>14.0%</u>	Ns	<u>12.8%</u>	<u>0.05&gt;</u>	<u>18.4%</u>
<u>CHD*****</u>	<u>4.7%</u>	<u>0.001&gt;</u>	<u>10.1%</u>	Ns	<u>11.4%</u>	Ns	<u>14.8%</u>	Ns	<u>11.9%</u>
<u>CRD*****</u>	<u>0.0%</u>	Ns	<u>1.9%</u>	Ns	<u>0.4%</u>	<u>0.01&gt;</u>	<u>2.0%</u>	<u>0.01&gt;</u>	<u>4.9%</u>
<u>Numbers of deteriorations</u>		<u>10</u>		<u>7</u>		<u>5</u>		<u>4</u>	

\*Nonsignificant (p>0.05) †Body mass index ‡Fasting plasma glucose §Low density lipoproteins ||High density lipoproteins \*\*White coat hypertension \*\*\*Hypertension \*\*\*\*Diabetes mellitus \*\*\*\*\*Chronic obstructive pulmonary disease \*\*\*\*\*Coronary heart disease \*\*\*\*\*Chronic renal disease

into the present study. On the other hand, although alcoholic drinks provide extra calories for body, smoking in humans and nicotine administration in animals may be associated with a decreased BMI (29). Evidence revealed an increased energy expenditure during smoking both on rest and light physical activity (30), and nicotine supplied by patch after smoking cessation decreased caloric intake in a dose-related manner (31). According to an animal study, nicotine may lengthen intermeal time, and simultaneously decrease amount of meal eaten (32). Additionally, BMI seems to be the highest in former and lowest in current smokers (33). Smoking may be associated with a postcessation weight gain (34). Similarly, although CHD was detected with similar prevalence in both genders in a previous study (35), prevalence of smoking and COPD was higher in males against the higher BMI, LDL, triglycerides, WCH, HT, and DM in females. This result may indicate both the strong atherosclerotic and weight decreasing roles of smoking (36). Similarly, the incidence of myocardial infarction is increased six-fold in women and three-fold in men who smoke 20 cigarettes per day (37). In another definition, smoking may be more dangerous for women probably due to the higher BMI and its consequences. Parallel to the above results, the proportion of smokers is consistently higher in men in the literature (19). So smoking is probably a powerful atherosclerotic risk factor with some suppressor effects on appetite. Smoking-induced appetite loss may be related with the smoking-induced severe vascular endothelial inflammation in whole body, since loss of appetite is one of the major symptoms of disseminated inflammation in the body. Physicians can even understand healing of patients by means of normalizing appetite. Several toxic substances found in the cigarette smoke get into the circulation by means of the respiratory tract and lungs, and cause a severe vascular endothelial inflammation in whole body until its clearance from the circulation. But due to the repeated smoking habit of the individuals, the clearance never terminates. So the patients become ill with loss of appetite, permanently. In another explanation, smoking-induced weight loss is an indicator of being ill instead of being healthy (31-33). After smoking cessation, appetite normalizes with a prominent weight gain but the returned weight is the patients' physiological weight, actually.

Although the obvious consequences of excess weight on health, nearly three-quarters of cases above the age of 30 years have excess weight (38). The prevalence of excess weight increases by decades, particularly after the third decade, up to the eighth decade of life (38). So 30th and 70th years of age may be the breaking points of life for weight, and aging may be the major determiner factor of excess weight. Probably, partially decreased physical and mental stresses after the age of 30 years, and debility and comorbid disorders-induced restrictions after the age of 70 years may be the major causes for the changes of BMI at these ages. Interestingly, the mean age and BMI increased just up to the plasma triglycerides values of 200 mg/dL and 150 mg/dL in the present study, respectively. So smoking remained as the major causative factor for the hypertriglyceridemia above the plasma triglycerides

value of 200 mg/dL. Beside that, the mean BMI values were 24.6, 27.1, 29.4, 29.9, and 30.0 kg/m<sup>2</sup> in the five study groups, respectively. In other words, only cases with the plasma triglycerides values lower than 60 mg/dL had a normal mean BMI. On the other hand, the mean age and triglycerides of the first group were 35.6 years and 51.0 mg/dL, respectively. They were 43.6 years and 78.3 mg/dL in the second, 47.7 years and 122.2 mg/dL in the third, and 51.2 years and 174.1 mg/dL in the fourth groups, respectively. In another definition, the triglycerides values increased about 7.8 mg/dL for each year of aging up to 200 mg/dL in the plasma. So aging alone may be another risk factor for chronic low-grade inflammation on vascular endothelium in the whole body.

Although ATP III reduced the normal upper limit of plasma triglycerides as 150 mg/dL in 2001 (16), whether or not much lower limits provide some additional benefits for the human body is unclear (39). Similar to a recent study (40), prevalence of smoking was the highest in the highest triglycerides having group in the present study and that may also indicate the inflammatory role of smoking in the metabolic syndrome, since triglycerides may behave as acute phase reactants in the plasma. FPG, BMI, HT, DM, COPD, and CRD increased parallel to the plasma triglycerides values from the first up to the fifth groups, continuously, in the present study. As one of our opinions, significantly increased mean age by the increased plasma triglycerides values may be secondary to aging-induced decreased physical and mental stresses, which eventually terminates with excess weight and its consequences. Interestingly, although the mean age increased from the lowest triglycerides having group up to the triglycerides value of 200 mg/dL, it then decreased. The similar trend was also seen with the mean LDL values. These trends may be due to the fact that although the borderline high triglycerides values (150-199 mg/dL) are seen together with physical inactivity and overweight, the high triglycerides (200-499 mg/dL) and very high triglycerides values (500 mg/dL or higher) may be secondary to genetic factors, smoking, and irreversible consequences of the metabolic syndrome including obesity, DM, HT, COPD, cirrhosis, CRD, PAD, CHD, and stroke (16). But although the underlying causes of the high and very high plasma triglycerides values may be a little bit different, probably risks of the terminal endpoints of the metabolic syndrome do not change in them. For example, prevalence of HT, DM, and COPD were the highest in the highest triglycerides having group in the present study. Eventually, although some authors reported that lipid assessment can be simplified by measurements of total cholesterol (41), the present study and most of the others indicated a causal relationship between higher triglycerides and irreversible end-points of the metabolic syndrome (42).

As a conclusion, plasma triglycerides may behave as acute phase reactants indicating disseminated endothelial injury and atherosclerosis. There may be significant associations between male gender, smoking, aging, excess weight, and plasma triglycerides values. FPG, LDL, WCH, HT, DM, COPD, CHD, and CRD all deteriorated parallel to

the increased male ratio, smoking, aging, excess weight, and plasma triglycerides values. Interestingly, the greatest number of deteriorations was observed just above the plasma triglycerides value of 60 mg/dL in the present study.

## References

1. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. *J Am Coll Cardiol* 2003; 42(7): 1149–1160.
2. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. *Circulation* 2001; 103(13): 1813–1818.
3. Helvaci MR, Seyhanli M. What a high prevalence of white coat hypertension in society! *Intern Med* 2006; 45(10): 671–674.
4. Helvaci MR, Kaya H, Seyhanli M, Cosar E. White coat hypertension is associated with a greater all-cause mortality. *J Health Sci* 2007; 53(2): 156–160.
5. Helvaci MR, Aydin Y, Gundogdu M. Smoking induced atherosclerosis in cancers. *HealthMED* 2012; 6(11): 3744–3749.
6. Fodor JG, Tzerovska R, Dorner T, Rieder A. Do we diagnose and treat coronary heart disease differently in men and women? *Wien Med Wochenschr* 2004; 154(17–18): 423–425.
7. Helvaci MR, Kaya H, Yalcin A, Kuvandik G. Prevalence of white coat hypertension in underweight and overweight subjects. *Int Heart J* 2007; 48(5): 605–613.
8. Helvaci MR, Kaya H, Duru M, Yalcin A. What is the relationship between white coat hypertension and dyslipidemia? *Int Heart J* 2008; 49(1): 87–93.
9. Helvaci MR, Kaya H, Sevinc A, Camci C. Body weight and white coat hypertension. *Pak J Med Sci* 2009; 25(6): 916–921.
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005; 365(9468): 1415–1428.
11. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004; 109(3): 433–438.
12. Tonkin AM. The metabolic syndrome(s)? *Curr Atheroscler Rep* 2004; 6(3): 165–166.
13. Franklin SS, Barboza MG, Pio JR, Wong ND. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. *J Hypertens* 2006; 24(10): 2009–2016.
14. Helvaci MR, Kaya H, Gundogdu M. Association of increased triglyceride levels in metabolic syndrome with coronary artery disease. *Pak J Med Sci* 2010; 26(3): 667–672.
15. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *Circulation* 1994; 89(3): 1333–1445.
16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106(25): 3143–3421.
17. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation 1999.
18. Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A. Metformin and parameters of physical health. *Intern Med* 2008; 47(8): 697–703.
19. Helvaci MR, Aydin Y, Varan G, Abyad A, Pocock L. Acarbose versus metformin in the treatment of metabolic syndrome. *World Family Med* 2018; 16(5): 10–15.
20. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *J Hypertens* 2003; 21(5): 821–848.
21. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2013; 187(4): 347–65.
22. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. *Intern Med* 1999; 38(2): 202–206.
23. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? *Arterioscler Thromb Vasc Biol* 1999; 19(4): 972–978.
24. Zhou B, Wu Y, Yang J, Li Y, Zhang H, Zhao L. Overweight is an independent risk factor for cardiovascular disease in Chinese populations. *Obes Rev* 2002; 3(3): 147–156.
25. Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases—report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. *Biomed Environ Sci* 2002; 15(3): 245–252.
26. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. *N Engl J Med* 1999; 341(15): 1097–1105.
27. Helvaci MR, Aydin LY, Maden E, Aydin Y. What is the relationship between hypertriglyceridemia and smoking? *Middle East J Age and Ageing* 2011; 8(6).
28. Helvaci MR, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of hepatosteatosis in sickle cell diseases. *World Family Med* 2018; 16(3): 12–18.
29. Grunberg NE, Greenwood MR, Collins F, Epstein LH, Hatsukami D, Niaura R, et al. National working conference on smoking and body weight. Task Force 1: Mechanisms relevant to the relations between cigarette smoking and body weight. *Health Psychol* 1992; 11: 4–9.
30. Walker JF, Collins LC, Rowell PP, Goldsmith LJ, Moffatt RJ, Stamford BA. The effect of smoking on energy expenditure and plasma catecholamine and nicotine levels during light physical activity. *Nicotine Tob Res* 1999; 1(4): 365–370.
31. Hughes JR, Hatsukami DK. Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight. *J Subst Abuse* 1997; 9: 151–159.

32. Miyata G, Meguid MM, Varma M, Fetissov SO, Kim HJ. Nicotine alters the usual reciprocity between meal size and meal number in female rat. *Physiol Behav* 2001; 74(1-2): 169-176.
33. Laaksonen M, Rahkonen O, Prattala R. Smoking status and relative weight by educational level in Finland, 1978-1995. *Prev Med* 1998; 27(3): 431-437.
34. Froom P, Melamed S, Benbassat J. Smoking cessation and weight gain. *J Fam Pract* 1998; 46(6): 460-464.
35. Helvaci MR, Kaya H, Gundogdu M. Gender differences in coronary heart disease in Turkey. *Pak J Med Sci* 2012; 28(1): 40-44.
36. Helvaci MR, Aydin Y, Gundogdu M. Atherosclerotic effects of smoking and excess weight. *J Obes Wt Loss Ther* 2012; 2: 145.
37. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. *BMJ* 1998; 316(7137): 1043-1047.
38. Helvaci MR, Kaya H, Ozer C. Aging may be the major determiner factor of excess weight. *Middle East J Age and Ageing* 2008; 5(2).
39. Helvaci MR, Tonyali O, Abyad A, Pocock L. The safest value of plasma triglycerides. *World Family Med* 2019; 17(7): 22-27.
40. Helvaci MR, Tonyali O, Abyad A, Pocock L. Smoking may be a cause of hypertriglyceridemia. *World Family Med* 2019; 17(8): 14-18.
41. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* 2009; 302(18): 1993-2000.
42. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet* 2010; 375(9726): 1634-1639.